FDA Eases Biosimilar Trial Requirements

Most copies of biologic drugs could reach market without comparative efficacy studies, under a streamlined FDA approach announced in October 2025.

Updated on Nov. 5, 2026 in Biotech

Isometric editorial illustration of sealed glass vials and a steel analytical instrument on a laboratory bench, evoking analytical testing replacing clinical trials for biosimilar drugs. — The FDA is moving to let most biosimilar drugs reach market without comparative efficacy studies, relying instead on analytical assessments of molecular similarity. AI Illustration. Upload story photo >

Live Poll

Should the FDA approve cheaper generic-style biologic drugs without new clinical trials?

FDA official Sarah Yim, director of the agency's Office of Therapeutic Biologics and Biosimilars, urged biosimilar sponsors to rely less on comparative efficacy studies. The streamlined approach the FDA announced in October 2025 could eliminate that requirement for most biosimilars, letting manufacturers use comparative analytical assessments instead. This is a policy direction stated by the agency, not a finalized rule.

Why it matters

Yim said clinical studies are not helping biosimilar programs, and the FDA has held numerous stakeholder conversations clarifying that such studies are not necessary. The shift points toward a development pathway where analytical data carries more of the weight in proving biosimilarity.

The FDA's new framework relies on comparative analytical assessments, which compare the molecular and structural properties of a biosimilar against its reference product. The BsUFA IV changes reduce six supplement categories to two, with review clocks of four and six months. The number of sponsors affected and the resulting time savings have not been quantified in the source.

The players

U.S. Food and Drug Administration (FDA)

The federal agency that regulates biologics and biosimilars in the United States, overseeing the approval pathway for copies of approved biologic drugs.

Sarah Yim

Director of the FDA's Office of Therapeutic Biologics and Biosimilars, who publicly urged sponsors to rely less on clinical efficacy studies.

The details

A biosimilar is a biologic drug designed to be highly similar to an already approved reference product. Under the streamlined approach, manufacturers could demonstrate similarity mainly through comparative analytical assessments, which examine a product's molecular and structural characteristics side by side with the reference product. Comparative efficacy studies, which measure clinical outcomes in patients, would remain required only where the FDA still judges them necessary. The FDA also plans to generate educational materials to help sponsors interpret the analytical data.

October 2025: FDA announced the streamlined biosimilar development approach.
Late September 2026: FDA published its BsUFA IV commitment letter.
Tuesday, 2026: Yim spoke at a fireside chat at the AAM GRx+Biosim conference.

The Tech Race

The FDA's push away from comparative efficacy studies follows its October 2025 streamlined biosimilar approach and is embedded in the BsUFA IV reauthorization. It positions the United States' regulatory path for biosimilars against the pace at which analytical methods are maturing.

Patients and prescribers may eventually see more biosimilar options reach the market sooner if clinical efficacy trials are no longer required for most products. The timeline for when this change takes effect has not been announced in the source.

The takeaway

Watch for the FDA's formal rulemaking or guidance that operationalizes the streamlined approach and specifies which biosimilars qualify. The educational materials the agency plans to publish on analytical data will show how readily sponsors can adopt the new pathway.